CNS — Stock Film
STOCK FILMSCENE 1/11CNS · $77.40
Stock Expert AI presents
CNS
Cohen & Steers, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Cohen & Steers, Inc. A quick introduction.

On the stock market since 2004, it operates in the world of money and finance. It has 411 employees. Now — the numbers.

on the stock market since 2004
411 employees
$4B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $27 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 27%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
58%Open-End Investment Funds
Open-End Investment Funds 58%Institutional Accounts 24%Closed-End Investment Funds 19%
58% of all revenue comes from a single line: Open-End Investment Funds.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
3 / 8
EXPECTATIONS MET OR BEATEN
3
Oct 2024
Jan 2025
Apr 2025
Jul 2025
Oct 2025
Jan 2026
Apr 2026
Jul 2026
3 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
98
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
5
very weak

For a bank, strength is measured by capital buffers and reserves — not cash minus debt.

VALUATION
48
weak

Clearly below the class average.

GROWTH
18
very weak

Clearly below the class average.

PRICE MOMENTUM
93
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The capital buffer looks thin next to its class; less room to absorb a rough stretch.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Growth has stalled4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 27% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 27% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 91 buys and 22 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Pays a steady dividend

It pays out $2.58 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 3 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 5/100.

3
THE RISKS · 3/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 18/100.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, CNS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CNS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 28, 2026 · stockexpertai.com · Stock Film